Media coverage about Hospira (NYSE:HSP) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Hospira earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave media stories about the healthcare company an impact score of 43.6108854215044 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-hospira-hsp-share-price/1606323.html.

About Hospira

Hospira, Inc provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company’s portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products.

Insider Buying and Selling by Quarter for Hospira (NYSE:HSP)

Receive News & Ratings for Hospira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hospira Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.